Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240704 | 0.96 | AURKA (0.47) | AURKAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14538354 | 0.84 | PTK6 (0.52) | AURKAAURKBPIK3CDTTK | |
| SCHEMBL8247778 | 0.83 | AURKA (0.45) | AURKAAURKBTTKIRAK1 | |
| SCHEMBL8426674 | 0.82 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DUSP30 | |
| SCHEMBL8241171 | 0.80 | AURKA (0.59) | AURKAAURKBTTKWNT1GSK3B | |
| SCHEMBL8246328 | 0.79 | AURKA (0.56) | AURKAAURKBTTKMETWNT1 | |
| SCHEMBL14507329 | 0.78 | AURKA (0.66) | AURKAAURKBUSP30IRAK1 | |
| SCHEMBL8239866 | 0.77 | AURKA (0.56) | AURKAAURKBTTK | |
| SCHEMBL8246690 | 0.77 | AURKA (0.70) | AURKAAURKBUSP30TTKCCNA2 | |
| SCHEMBL8239849 | 0.76 | AURKA (0.54) | AURKAAURKBTTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | AURKA 91/4885PDE4A 1311/4885PDE4B 1634/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKA 41/4885PDE4A 1264/4885PDE4B 1735/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKA 5/4885PDE4A 2883/4885PDE4B 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.